Noxopharm (ASX:NOX) submits Veyonda patent for septic shock opportunity

Subscribe to

Be the first on the news that moves the market

  • Noxopharm (NOX) has filed an international patent for the use of its clinical-stage drug, Veyonda, to treat septic shock
  • Preclinical data has shown that Veyonda can block the cytokine storm that leads to septic shock and causes blood clots, organ damage, and even death
  • Septic shock occurs when people have an excessive immune response following a bacterial infection or a virus like COVID-19
  • There is currently a lack of effective treatment options for septic shock, which presents a significant commercial opportunity for Noxopharm
  • The company’s shares are up 3.97 percent and trade at 65.5 cents

Noxopharm (NOX) has filed an international patent application for the expanded use of Veyonda in the treatment of septic shock.

Veyonda is a clinical-stage drug aimed at providing better treatment options for cancer patients.

One of its anti-cancer measures blocks a signaling pathway called STING, which triggers an immune response and repair of damaged tissue. However, some people experience an excessive STING reaction that causes septic shock.

In particular, septic shock occurs in response to infections from viruses such as COVID-19 and influenza, as well as a variety of bacterial infections and parasites such as malaria.

During the septic shock process, chemicals that promote inflammation, called cytokines, are released into the blood, which lead to clotting and can lead to organ damage and death.

Due to the lack of effective treatments, septic shock is reported to be responsible for around 10 million deaths each year, as well as an additional three million deaths from COVID-19. This represents a significant commercial opportunity.

While there are some supportive treatments for septic shock, there is an unmet need for reducing cytokine levels. For example, previous studies have shown that COVID-19 patients given drugs to block individual cytokines either failed or were moderately effective.

Veyonda’s goal is to block the production of multiple cytokines. Preclinical data has shown that the main active ingredient, idronoxil, is likely to do so.

Noxopharm is currently testing blood samples from patients from its NOXCOVID study, which tested Veyonda’s potential to prevent COVID-19 from worsening to cytokine release syndrome (CRS) and septic shock. The results will be published in the coming weeks.

The company’s shares are up 3.97 percent and trade at 65.5 cents at 11:20 a.m. AEST.

You might also like

Comments are closed.